Zai Lab LimitedZLAB was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $20.13 to $23.36 in the past one-month time frame.
The stock gained after the company reported the dosing of the first patient in a Phase III trial of ZL-2306 in patients with small-cell lung cancer (SCLC).
The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Zai Lab currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.
Zai Lab Limited Unsponsored ADR Price
Investors interested in the Medical - Biomedical and Genetics industry may consider Illumina, Inc. ILMN , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.